A hormone the body already makes.
What the GLP-1 class is, and what tends to come up at the appointment.
Education and visit preparation. Ojava does not prescribe, dose, adjust medication, or decide whether anything here applies to you.
- HbA1c
- Fasting glucose
- Weight
- Kidney function
- Lipids
Education, and preparation. That is all.
This page explains what a class of medication is and which markers tend to come up in the conversation, so you can walk into your own appointment with better questions. Your clinician and your pharmacist decide everything else.
- No prescription, no dose, and no schedule.
- No advice to start, stop or change anything.
- No judgement about whether a medication is working for you.
What the class is
A class named afterthe hormone it imitates
GLP-1 is a gut hormone released after eating. The medications in this class are built to resemble it, which is where both the name and most of the conversation come from. Knowing that much makes the rest of the appointment easier to follow.
Drug class
GLP-1 receptor agonists: a family of medications that resemble glucagon-like peptide-1, a hormone the gut releases after a meal. Semaglutide and tirzepatide are two of the names you may see on a label.
What they do
They act on the same receptor the natural hormone does, which affects how the pancreas releases insulin in response to glucose, how quickly the stomach empties, and how full a person feels.
Approved uses
Type 2 diabetes, and weight management in defined groups. Which specific product is approved for which use varies, and the current label for the exact product is the authority on that, not this page.
What comes up
The markers peopletend to bring along
These are the results that often sit near this class of medication in a conversation. Ojava keeps whichever of them are in your own record together, in date order, so the question you ask is about your history rather than a general one.
Hemoglobin A1c
Reflects average blood glucose over roughly three months. It is one of the standing reference points in a conversation about glucose regulation.
Fasting glucose
A single blood sugar reading taken before eating. It describes a different moment than A1c does, which is why both often appear in the same panel.
Weight and BMI
Body weight, and weight relative to height. Many people track these for their own reasons, and they frequently come up in this conversation.
Kidney function
Creatinine and eGFR describe how well the kidneys are filtering. They appear in a lot of routine panels and are a common thing to ask about.
Lipid panel
Cholesterol and triglycerides. A standard panel that tends to be part of the wider metabolic picture people bring to an appointment.
Liver enzymes
ALT and AST reflect liver activity. Some clinicians include them in the broader picture, which is a reasonable thing to ask about.
No target value, no reference band and no reading of whether a medication is working appears on this page. Ojava organizes what you already have and explains what a marker measures. Interpreting your own results is a conversation for your clinician.
Before the visit
Walk in withthe specific question
A good appointment usually turns on one precise question. These are the ones worth having written down, and the record that makes each of them specific.
- What is this class of medication meant to do for someone in my situation?
- Which of my results would you want to look at, and how often?
- What side effects are worth telling you about, and how quickly?
- Are there interactions with anything else on my list, including supplements?
- What would make you want to revisit this decision?
- Who should I contact between visits, and about what?
What your record already holds
- Your medication list, with the dates you noted for each entry.
- A1c, fasting glucose and lipid results in date order, from panels you accepted.
- Weight history from whatever you already track, alongside the meals you logged.
- Your own notes about how you have felt, kept next to the timeline rather than in a separate app.
Sources
What this page stands on.
Official labelling and professional-society guidance, linked so you can read the original rather than take a summary on trust.
DailyMed Drug Labeling
U.S. National Library of Medicine, 2026
Supports official label-backed medication education. Label mentions are not the same as patient-specific safety clearance.
Drug Interactions: What You Should Know
U.S. Food and Drug Administration, 2013
Supports consumer education around drug-drug, drug-food, supplement, and condition interactions. It does not make Ojava a comprehensive interaction checker.
Mixing Medications and Dietary Supplements Can Endanger Your Health
U.S. Food and Drug Administration, 2022
Supports asking a clinician or pharmacist about supplement and medication combinations instead of treating a missing match as safe.
American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults
American Geriatrics Society Beers Criteria Update Expert Panel, 2023
Supports medication-review caution and the idea that certain medication risks depend on age, condition, kidney function, and drug-drug context. It is not a patient-specific safety clearance.
STOPP/START criteria for potentially inappropriate prescribing in older people: version 3
O Mahony, Cherubini, Guiteras, et al., 2023
Supports older-adult medication-review prompts around potentially inappropriate prescriptions and possible prescribing omissions. Ojava does not apply the criteria or classify a patient-specific issue.
Deprescribing Guidelines and Algorithms
Deprescribing.org, 2026
Supports deprescribing conversation preparation with a clinician or pharmacist. Ojava does not stop, taper, substitute, or recommend medication changes.
DailyMed GLP-1 Drug Labels
DailyMed, U.S. National Library of Medicine, 2026
Supports official-label education for common GLP-1 and incretin medications. It does not clear patient-specific safety or prescribe treatment.
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
Grunvald, Shah, Hernaez, et al., 2022
Supports clinician-led obesity medication discussion. Ojava does not recommend weight-loss medication, set treatment goals, or decide eligibility.
Standards of Care in Diabetes, 2026
American Diabetes Association Professional Practice Committee, 2026
Supports diabetes-care education around A1c, glucose, kidney context, medication review, and clinician-led decisions. Ojava does not diagnose or treat diabetes.
Bring the record,not just the question
Keep your GLP-1 history, your own results and your notes in one place, and the next appointment starts from what actually happened rather than from memory.
Your list, your notes
What you take and what you have noticed, held together with the results and documents that sit near them.
In date order
Results line up chronologically, so a question about a change is asked about a real change rather than an impression.
The decision stays with care
Prescribing, dosing, refills, and any change at all remain with your licensed clinician or pharmacist.
This is general educational information about a class of medication, not medical advice, a prescription, or a recommendation. Ojava does not diagnose, prescribe, dose, adjust medication, order labs, or replace your clinician.